Journal profile · Oncology
Current Problems in Cancer
ISSN 0147-0272 · eISSN 1535-6345 · Mosby Inc. · UNITED STATES · Bimonthly · Founded 1976
Current Problems in Cancer: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2.33; hybrid open access; APC about USD 3,740; median 111 days to acceptance (71 articles, last 24 months); community-reported acceptance: fairly easy; 52 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Current Problems in Cancer is published by Mosby Inc. and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Diverse Scientific and Economic Studies, Ferroelectric and Negative Capacitance Devices and Human auditory perception and evaluation, together about 31.3% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Current Problems in Cancer seeks to promote and disseminate innovative, transformative, and impactful data on patient-oriented cancer research and clinical care. Specifically, the journal's scope is focused on reporting the results of well-designed cancer studies that influence/alter practice or identify new directions in translational and clinical cancer research. These studies can include novel therapeutic approaches, new strategies for early diagnosis, cancer clinical trials, and supportive care, among others. Pre-clinical studies are discouraged. The journal's format also allows, on occasion, for a multi-faceted overview of a single topic via a curated selection of review articles, while also offering articles that present dynamic material that influences the oncology field.Original case reports featuring prevention, diagnosis and treatment of cancer, supportive care, quality of life and rehabilitation can be submitted to the journal's open access companion title, Current Problems in Cancer: Case Reports.(CPCCR). Any case reports submitted to Current Problems in Cancer (CPC) will be considered for publication in either CPC or CPCCR.
From the journal's Aims & Scope
Research area (LetPub): Oncology
Editor-in-chief Shivaani KummarPublisher website
Editorial board by country: none in mainland China; most named United States 20, India 7, United Kingdom 4, South Korea 2, Japan 1 (37 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Diverse Scientific and Economic StudiesEconomics, Econometrics and Finance16.3%
- Ferroelectric and Negative Capacitance DevicesEngineering7.7%
- Human auditory perception and evaluationEngineering7.4%
- Educational Robotics and EngineeringComputer Science7.4%
- Big Data and Digital EconomyComputer Science6.7%
- Lung Cancer Treatments and MutationsMedicine4.6%
- Lung Cancer Research StudiesMedicine3.7%
- Cancer Genomics and DiagnosticsBiochemistry, Genetics and Molecular Biology3.5%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.33LetPub ·
- Impact factor (publisher)
- 2.4Publisher website ·
- CiteScore 2026-06
- 4.7LetPub ·
- CiteScore (publisher)
- 4.7Publisher website ·
- SJR 2026-06
- 0.81LetPub ·
- SNIP 2026-06
- 0.72LetPub ·
- h-index
- 29LetPub ·
- h-index
- 70OpenAlex ·
- i10-index
- 510OpenAlex ·
- 2-year mean citedness
- 2.54OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 21.48%LetPub ·
Volume
- Articles per year
- 34LetPub ·
Articles by year OpenAlex count · 1,786 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 42 | 12 | 10 |
| 2025 | 52 | 9 | 64 |
| 2024 | 74 | 17 | 353 |
| 2023 | 68 | 16 | 329 |
| 2022 | 61 | 17 | 484 |
| 2021 | 89 | 16 | 1,049 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
111 daysMedian, submission to acceptance · P25–P75 72 days – 190 days
- Acceptance to online
- median 10 days (71 articles)
- Submission to online
- median 130 days
- Sample
- 71 articles with submission and acceptance dates (79 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- over 12 weeksLetPub ·
- Average acceptance (community reports)
- Fairly easyLetPub ·
- Submission to first decision
- 8 daysPublisher website ·
- First decision after review
- 78 daysPublisher website ·
- Submission to acceptance
- 112 daysPublisher website ·
- Acceptance to publication
- 10 daysPublisher website ·
- Peer review
- Single anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 3,740 / EUR 3,500 / GBP 2,990 / JPY 463,870 | — | — | |
| Publisher website | USD 3,610 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare4 items from the author guidelines
- Abstract
- ≤ 250 words
- Suggested reviewers
- Optional
- Graphical abstract
- Optional
- Cover letter
- Required
Article types accepted16, with length limits
- brief reportResearch Paper should not exceed 3000 words excluding references (usually less than 50). Typically we allow up to 6 tables/figures. Consider including more data…Length not stated
- brief reports and opinionBrief Reports and Opinion: Opinion on scientific, educational, or policy issues, as well as early reports of clinical or survey studies.Length not stated
- case reportResearch Paper should not exceed 3000 words excluding references (usually less than 50). Typically we allow up to 6 tables/figures. Consider including more data…Length not stated
- case reportsCase Reports: CPC is pleased to announce the launch of its sister journal Current Problems in Cancer: Case Reports (CPCCR). Case Reports submitted to CPC will n…Length not stated
- discussionDiscussion: Remark on work published in the Journal and participate in discussion with the authors.Length not stated
- imagesImages: Images of Interesting Clinical Conditions are images that are diagnostic of common medical conditions. They are not intended as a form of case report.Length not stated
- letterResearch Paper should not exceed 3000 words excluding references (usually less than 50). Typically we allow up to 6 tables/figures. Consider including more data…Length not stated
- mini reviewResearch Paper should not exceed 3000 words excluding references (usually less than 50). Typically we allow up to 6 tables/figures. Consider including more data…main text ≤ 2,500 words
- opinionResearch Paper should not exceed 3000 words excluding references (usually less than 50). Typically we allow up to 6 tables/figures. Consider including more data…Length not stated
- research paperResearch Paper should not exceed 3000 words excluding references (usually less than 50). Typically we allow up to 6 tables/figures. Consider including more data…main text ≤ 3,000 words
- reviewResearch Paper should not exceed 3000 words excluding references (usually less than 50). Typically we allow up to 6 tables/figures. Consider including more data…main text ≤ 5,000 words
- review articleResearch Paper should not exceed 3000 words excluding references (usually less than 50). Typically we allow up to 6 tables/figures. Consider including more data…Length not stated
- short communicationResearch Paper should not exceed 3000 words excluding references (usually less than 50). Typically we allow up to 6 tables/figures. Consider including more data…main text ≤ 1,500 words
- short reviewResearch Paper should not exceed 3000 words excluding references (usually less than 50). Typically we allow up to 6 tables/figures. Consider including more data…main text ≤ 2,500 words
- surveyResearch Paper should not exceed 3000 words excluding references (usually less than 50). Typically we allow up to 6 tables/figures. Consider including more data…Length not stated
- tumor board reportTumor Board Report: Tumor board reports are not case reports, but rather in-depth discussions of rare, difficult, or illuminating oncology conditions which shou…Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Group authorship
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- License & copyright License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
Source ↗Publisher website ·- Open access Open access
We refer you to our open access information page to learn about open access options for this journal.
Source ↗Publisher website ·- Peer review Peer review
Single anonymized review process Model summary
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
Source ↗Publisher website ·- Preprints Preprints
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Mosby Inc.
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Bimonthly
- Founded
- 1976
- ISSN
- 0147-0272
- Electronic ISSN
- 1535-6345
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Current Problems in Cancer
What CAS zone is Current Problems in Cancer in?
In the 2025 upgraded edition of the CAS Journal Ranking, Current Problems in Cancer is in Zone 4 of Medicine, and in Zone 4 of the minor category Oncology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Current Problems in Cancer?
The latest impact factor listed by LetPub is 2.33; CiteScore 4.7, h-index 70.
How long does peer review take at Current Problems in Cancer?
Based on the dates recorded on 71 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 111 days (interquartile range 72–190 days); authors report an average review time of over 12 weeks; the community-reported acceptance is “Fairly easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Current Problems in Cancer?
According to the journal's author guidelines: Abstract: ≤ 250 words; Suggested reviewers: Optional; Graphical abstract: Optional; Cover letter: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Current Problems in Cancer based?
Of the 37 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United States (20), India (7) and United Kingdom (4). Counted from the institutions listed on the board page; for reference only.
Which databases index Current Problems in Cancer?
According to LetPub and DOAJ records, Current Problems in Cancer is indexed in SCIE and Scopus.
Is Current Problems in Cancer open access, and what is the APC?
Current Problems in Cancer is a hybrid journal. For open-access publication: APC about USD 3,740.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .